

PHARMACEUTICAL & THERAPEUTICS (P&T) COMMITTEE
Connecticut Medical Assistance Program

Wednesday November 19, 2014
6:00 pm – 10:00 pm

CCSU Institute of Technology and Business Development
Goodyear Conference Room – 3rd Floor
185 Main Street
New Britain, CT 06051

AGENDA

Opening Remarks

Department of Social Services

New Business

Approval of revised P&T Committee Bylaws

Carl Sherter, Chair

Approval of Minutes

Carl Sherter, Chair

April 30, 2014 meeting

Therapeutic Class Reviews

Kathy Novak, Magellan

Public Presentations

1. Antipsychotics

- a. Class Testimony
- b. Class Testimony
- c. Latuda
- d. Invega Sustena

Susan Kelly, J.D. NAMI CT
Paul Desan, MD CT Psychiatric Society
Parsh Sachdeva, PharmD Sunovion
Arlene Price, PharmD Janssen

2. Antidepressants, Other

- a. Antidepressant Class Testimony
- b. Class Testimony
- c. Viibryd, Fetzima
- d. Brintellix
- e. Pristiq

Dale Wallington, MD
Paul Desan, MD CT Psychiatric Society
Bassam Awwa, MD
Christopher Carello, PhD Takeda
Aniello Marotta, PharmD Pfizer

3. Antidepressants, SSRIs

- a. Class Testimony

Paul Desan, MD CT Psychiatric Society

4. Anticonvulsants

- a. Vimpat
- b. Aptiom

Bryan Hill, PharmD UCB
John McCarty, Sunovion

5. Botulinum Toxins

- a. Botox

Jawad Wunej, PharmD Allergan

6. Bronchodilators, Beta Agonist

- a. Ventolin HFA

Adam Denman, GSK

7. COPD Agents

- a. Anoro Ellipta
- b. Daliresp, Tudorza

Adam Denman, GSK
Patrick Troy, MD

8. Cytokine and CAM Antagonists

- a. Xeljanz

Aniello Marotta, PharmD Pfizer

- b. Simponi, Stelara
- 9. Epinephrine, Self-injected
 - a. Epipen and Epipen Jr.
- 10. Glucocorticoids, Inhaled
 - a. Breo Ellipta
- 11. Intranasal Rhinitis Agents
 - a. QNASL
- 12. Neuropathic Pain
 - a. Lyrica
- 13. NSAIDs
 - a. Flector
- 14. Oncology Agents, Oral
 - a. Connecticut Oncology Assoc.
 - b. Sprycel
 - c. Zydelig
 - d. Bosulif, Sutent, Inlyta, Xalkori
 - e. Zykadia
- 15. Oncology Agents, Breast Cancer
 - a. Connecticut Oncology Assoc.
- 16. Smoking Cessation
 - a. Chantix
- 17. Stimulants and Related Agents
 - a. Class Testimony
 - b. Quillivant XR

Arlene Price, PharmD Janssen

Margaret Marsh, PharmD Mylan

Adam Denman, GSK

Alissa Amara, Teva

Aniello Marotta, PharmD Pfizer

Aniello Marotta, PharmD Pfizer

Dawn Holcombe

Bruce Sill, PharmD BMS

Jeffery Olson, PharmD Gilead

Aniello Marotta, PharmD Pfizer

Kenneth Miller, PharmD Novartis

Dawn Holcombe

Aniello Marotta, PharmD Pfizer

Paul Desan, MD CT Psychiatric Society

Aniello Marotta, PharmD Pfizer

New Generics to Market

- 18. Alzheimer's Agents
- 19. Anti-allergens, Oral
- 20. Antihistamines, Minimally Sedating
- 21. Antihypertensives, Sympatholytic
- 22. Antihyperuricemics
- 23. Antiparkinson's Agents
- 24. Antipsoriatics, Oral
- 25. Antipsoriatics, Topical
- 26. Anxiolytics
- 27. Bile Salts
- 28. Emollients
- 29. Glucocorticoids, Oral
- 30. Histamine II Receptor Blocker
- 31. Immunomodulators, Atopic Dermatitis
- 32. Immunomodulators, Topical
- 33. Iron, Oral
- 34. Leukotriene Modifiers
- 35. Ophthalmic Antibiotics
- 36. Ophthalmic Antibiotic-Steroid Combinations
- 37. Ophthalmics for Allergic Conjunctivitis
- 38. Ophthalmic, Anti-Inflammatories
- 39. Ophthalmics, Glaucoma Agents
- 40. Otic Antibiotics
- 41. Otic Anti-Infectives & Anesthetics

Kathy Novak, Magellan

- 42. Sedative Hypnotics
- 43. Steroids, Topical Low
- 44. Steroids, Topical Medium
- 45. Steroids, Topical High
- 46. Steroids, Topical Very High

P&T Recommendations

C. Sherter, Chair

Other Business

Recommendations for next class reviews

Kathy Novak / Magellan

Adjourn